| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Research and development | $16.4M+476.3% | $2.8M-11.7% | $3.2M |
| General and administrative | $12.3M+210.6% | $4.0M+253.1% | $1.1M |
| Loss from operations | -$28.7M-321.3% | -$6.8M-56.9% | -$4.3M |
| Interest income | $249 | — | — |
| Interest expense | -$2.1M | — | -$3.4M |
| Non-operating income | $34K | — | — |
| Non-operating expenses | -$1.5M-2774.1% | -$51K | — |
| Change in fair value of warrant liability | $1.4M | — | — |
| TOTAL OTHER INCOME/EXPENSE | -$48K+97.7% | -$2.1M+40.0% | -$3.4M |
| NET LOSS | -$28.8M-223.7% | -$8.9M-14.0% | -$7.8M |
| Cumulative Series A preferred stock dividend requirement | -$31K | — | — |
| NET LOSS available to common shareholders | -$28.8M-222.6% | -$8.9M-12.6% | -$7.9M |
| Weighted average # of shares (in Shares) | 29.3M+320.9% | 7.0M | — |
| Basic loss per common share outstanding (in Dollars per share) | -$0.98+23.4% | -$1.28+12.3% | -$1.46 |
| Diluted loss per common share outstanding (in Dollars per share) | -$0.98+23.4% | -$1.28+12.3% | -$1.46 |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.